Design of wide-spectrum inhibitors targeting coronavirus main proteases
- PMID: 16128623
- PMCID: PMC1197287
- DOI: 10.1371/journal.pbio.0030324
Design of wide-spectrum inhibitors targeting coronavirus main proteases
Erratum in
- PLoS Biol. 2005 Nov;3(11):e428
Abstract
The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing highly prevalent diseases and often severe or fatal in humans and animals. No licensed specific drugs are available to prevent their infection. Different host receptors for cellular entry, poorly conserved structural proteins (antigens), and the high mutation and recombination rates of CoVs pose a significant problem in the development of wide-spectrum anti-CoV drugs and vaccines. CoV main proteases (M(pro)s), which are key enzymes in viral gene expression and replication, were revealed to share a highly conservative substrate-recognition pocket by comparison of four crystal structures and a homology model representing all three genetic clusters of the genus Coronavirus. This conclusion was further supported by enzyme activity assays. Mechanism-based irreversible inhibitors were designed, based on this conserved structural region, and a uniform inhibition mechanism was elucidated from the structures of Mpro-inhibitor complexes from severe acute respiratory syndrome-CoV and porcine transmissible gastroenteritis virus. A structure-assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV M(pro)s, potent antiviral activity, and extremely low cellular toxicity in cell-based assays. Further modification could rapidly lead to the discovery of a single agent with clinical potential against existing and possible future emerging CoV-related diseases.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1250287/bin/pbio.0030324.g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1250287/bin/pbio.0030324.g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1250287/bin/pbio.0030324.g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1250287/bin/pbio.0030324.g004.gif)
Similar articles
-
The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29. Antiviral Res. 2015. PMID: 25554382 Free PMC article. Review.
-
Drug design targeting the main protease, the Achilles' heel of coronaviruses.Curr Pharm Des. 2006;12(35):4573-90. doi: 10.2174/138161206779010369. Curr Pharm Des. 2006. PMID: 17168763 Review.
-
Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides.Med Chem. 2005 May;1(3):209-13. doi: 10.2174/1573406053765468. Med Chem. 2005. PMID: 16787316
-
A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.Acta Pharmacol Sin. 2003 Jun;24(6):497-504. Acta Pharmacol Sin. 2003. PMID: 12791174
-
Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.Science. 2003 Jun 13;300(5626):1763-7. doi: 10.1126/science.1085658. Epub 2003 May 13. Science. 2003. PMID: 12746549
Cited by
-
Quinazolines and thiazolidine-2,4-dions as SARS-CoV-2 inhibitors: repurposing, in silico molecular docking and dynamics simulation.RSC Adv. 2024 Apr 23;14(19):13237-13250. doi: 10.1039/d4ra02029d. eCollection 2024 Apr 22. RSC Adv. 2024. PMID: 38655479 Free PMC article.
-
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.Cell Discov. 2024 Apr 9;10(1):40. doi: 10.1038/s41421-024-00673-0. Cell Discov. 2024. PMID: 38594245 Free PMC article.
-
On the origins of SARS-CoV-2 main protease inhibitors.RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25. RSC Med Chem. 2023. PMID: 38283212 Review.
-
Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2.Commun Chem. 2024 Jan 18;7(1):15. doi: 10.1038/s42004-024-01104-7. Commun Chem. 2024. PMID: 38238420 Free PMC article.
-
Repurposing of Rutan showed effective treatment for COVID-19 disease.Front Med (Lausanne). 2023 Nov 29;10:1310129. doi: 10.3389/fmed.2023.1310129. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38093975 Free PMC article.
References
-
- Lai MMC, Holmes KV. Coronaviridae The viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology, 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 1163–1179.
-
- Spaan WJM, Cavanagh D. Virus taxonomy: Eighth report of the International Committee on Taxonomy of Viruses. London: Elsevier-Academic Press; 2004. Coronaviridae ; pp. 945–962.
-
- Pereira HG. Coronaviridae . In: Porterfield JS, editor. Andrewes' viruses of vertebrates, 5th ed. London: Baillière Tindall; 1989. pp. 42–57.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases